| Document |
Document Title |
|
WO/2022/063876A1 |
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and...
|
|
WO/2022/058785A1 |
The invention relates to new olaparib oxalic acid cocrystals. The olaparib oxalic acid cocrystals vary in ratio from 1:1 to 2:3 olaparib: oxalic acid. In particular, the invention relates to a 2:3 olaparib oxalic acid cocrystal, a 1:1 ol...
|
|
WO/2022/040747A1 |
The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formul...
|
|
WO/2022/037647A1 |
Provided are a crystalline form of a selective NaV inhibitor and a preparation method therefor. Specifically, provided are crystalline forms A to E of the compound 4-((4-(5-chloro-2-(4-fluoro-2-(methoxy-d 3)phenoxy)-4-(trifluoromethyl)be...
|
|
WO/2022/036204A1 |
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...
|
|
WO/2022/032484A1 |
Disclosed in the present invention are a pyridazine-3-formamide compound suitable for inhibiting or regulating the Janus kinase (JAK), in particular tyrosine kinase 2 (TYK2), and a preparation method therefor and the medical use thereof....
|
|
WO/2022/032144A1 |
Provided herein are compounds that modulate PRTM5 activity. The compounds may inhibit the binding PRMT5 with a PRMT5 substrate adaptor. The compounds can modulate PRMT5 methyltransferase activity, modulate transcription of a gene regulat...
|
|
WO/2022/026500A1 |
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...
|
|
WO/2022/026465A1 |
The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating ca...
|
|
WO/2022/017494A1 |
The present invention relates to a crystal form of a pyridazine derivative free base and a preparation method therefor and the use thereof. Specifically, the present invention relates to a compound as represented by general formula (I), ...
|
|
WO/2022/016345A1 |
Disclosed is an application of a composition for preventing and/or eliminating platelet aggregation in an in vitro blood sample. The composition comprises at least one compound selected from the group consisting of formula (I) and a salt...
|
|
WO/2022/002860A1 |
The use of P2X4 antagonists for the treatment of dry eye syndrome, more in particular substituted N-phenylacetamide compounds of general formula (I), pharmaceutical compositions and combinations comprising said compounds for use in the t...
|
|
WO/2022/002859A1 |
Substituted N-phenylacetamide compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and ...
|
|
WO/2021/261563A1 |
In the production of crops in agriculture, horticulture and the like, the occurrence of damages by pests and the like has been still a major issue, and therefore the development of novel agricultural/horticultural insecticides has been d...
|
|
WO/2021/260609A1 |
The invention relates to a novel process, novel process step(s) and novel intermediate(s) useful for the preparation of 1,4-disubstituted pyridazine compounds, such as 5-(1 H-Pyrazol-4-yl)-2-(6- ((2,2,6,6-tetramethylpiperidin-4-yl)oxy)py...
|
|
WO/2021/223650A9 |
The present application relates to a nitrogen-containing compound. The structural formula of the nitrogen-containing compound is as shown in formula I, in which ring A and ring B are each independently selected from a benzene ring or a f...
|
|
WO/2021/256900A1 |
The present invention relates to a novel oxopyridazinyl-phenyl-carbonohydrazonoyl dicyanide compound and a use thereof.
|
|
WO/2021/250466A1 |
The present disclosure includes certain substituted (phthalazin-1-ylmethyl)ureas, N- (phthalazin-1-ylmethyl)amides, and analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV)...
|
|
WO/2021/249995A1 |
The present disclosure relates to azabicyclyl-substituted heterocyclic compounds of formula (I), wherein A1, A2, m, R3, R4, R5, L, R6, T, the ring Y, p, R7 and Q have the meanings as defined in the specification, to compositions comprisi...
|
|
WO/2021/247634A1 |
Provided herein are compounds of Formula (I''), Formula (I'), Formula (I), Formula (II'), and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labele...
|
|
WO/2021/244391A1 |
Provided in the present invention is a small-molecule GLP-1R agonist, which is a compound of general formula (I), or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, solvate and deuterated compound thereof. The compound ...
|
|
WO/2021/239885A1 |
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and...
|
|
WO/2021/233787A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controllin...
|
|
WO/2021/233861A1 |
The present invention relates to azabicyclic (thio)amide compounds and the uses thereof for controlling phytopathogenic microorganisms such as phytopathogenic fungi. It also relates to processes and intermediates for preparing these comp...
|
|
WO/2021/233786A1 |
Compounds of the Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling...
|
|
WO/2021/231572A1 |
Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, amon...
|
|
WO/2021/225969A1 |
The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disc...
|
|
WO/2021/225407A1 |
The present invention relates to a compound for inhibiting ENPP1, a composition for inhibiting ENPP1, and a novel phthalazine derivative compound related to a method for inhibiting ENPP1, a pharmaceutically acceptable salt thereof, a hyd...
|
|
WO/2021/221011A1 |
The present invention provides, as a stable and easy-to-handle tyrosine modifier, a compound that is represented by general formula (I), (II), or (III) (in the formula, A represents a conjugated ring, L represents a linker or the like ha...
|
|
WO/2021/216781A1 |
The present disclosure provides compounds of formula (I), (II), and (la): Methods of preparing these molecules and their use for treatment of Parkinson's Disease are described.
|
|
WO/2021/210650A1 |
A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, a...
|
|
WO/2021/204626A1 |
Novel carboxamide substituted compounds of Formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Tyrosine Kinase 2 (Tyk2).
|
|
WO/2021/202652A1 |
This application discloses Tyk-2 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, method of preparing them, and use of these compounds as therapeutic agents fo...
|
|
WO/2021/202787A1 |
The present disclosure provides aropisomers of pyridazinone derivatives of a compound of Formula 1a and Formula 1b, N-oxides or salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the disclosure. Also disclosed is a composition c...
|
|
WO/2021/202731A1 |
Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combina...
|
|
WO/2021/193897A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular a compound suitable for prevention and/or treatment of an inflammatory disease and/or a neurodegenerative disease. The inventors of th...
|
|
WO/2021/188769A1 |
Compounds that inhibit HIF-2a, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse arr...
|
|
WO/2021/163519A1 |
Disclosed are compounds of Formula (1) including all geometric and stereoisomers, N-oxides, and salts thereof, wherein W, R1, R2, R3, R4, R5 m, n and p are as defined in the disclosure. Also disclosed are compositions containing the comp...
|
|
WO/2021/157591A1 |
The purpose of the present invention is to provide a method with which an aromatic heterocyclic ring-substituted difluoroacetic acid derivative can be produced using a simple and inexpensive method. The present invention relates to a m...
|
|
WO/2021/157590A1 |
The purpose of the present invention is to provide a method which is capable of producing a difluoromethyl-substituted aromatic heterocyclic compound by a simple and low-cost process. The present invention relates to a method for produ...
|
|
WO/2021/153786A1 |
The present invention provides a compound having an excellent control effect against pests. A compound represented by formula (1) of the present invention (in the formula, Q represents a group indicated by Q1 or a group indicated by Q2 (...
|
|
WO/2021/141041A1 |
Provided is a therapeutic agent and/or prophylactic agent for tauopathies that is based on the activation of voltage-gated sodium channels (Nav). The therapeutic agent and/or prophylactic agent for tauopathies has an Nav activator as an ...
|
|
WO/2021/136238A1 |
Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen o...
|
|
WO/2021/124344A1 |
The present invention relates to compound of formula I and II, or its pharmaceutically acceptable salt; wherein R is selected from the group consisting of -H, -F, -Cl, -Br, -I, -NO2, -CH3, or -C2H5; R1 is selected from the group consisti...
|
|
WO/2021/127429A1 |
The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating ca...
|
|
WO/2021/123174A1 |
The present invention relates to the field of medicine. More specifically, the present invention relates to compounds that are sigma-1 receptor agonists and their use for the treatment of central nervous system disorders, including cogni...
|
|
WO/2021/124346A1 |
The present invention relates to a compound of formula I, wherein R is selected from the group consisting of -H, -F, -Cl, -Br, -I, -NO2, -CH3, and -C2H5; and R1 is selected from the group consisting of –H, and -CH3. The invention also ...
|
|
WO/2021/127273A1 |
Described herein are compounds of formulae (I), (lla) and (Mb) as prolyl hydroxylase inhibitors, HIF-lalpha stabilizers and PGK up regulators for use in treating inflammatory diseases, cancer or infections: Preferred compounds are e.g. t...
|
|
WO/2021/104288A1 |
The present invention provides a 1,2,4-triazine-3,5-dione compound, a preparation method therefor, and an application thereof. The 1,2,4-triazine-3,5-dione compound having a structure represented by formula (I) provided by present invent...
|
|
WO/2021/105906A1 |
The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods f...
|
